Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Irene Mamkin

Pediatric Endocrinology West Orange, NJ Medical Doctor

NPI 1326210485 CMS profile 196500

375 Mount Pleasant Ave, West Orange, NJ 07052

Open in the dashboard

General payments

$13,456

382 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Irene Mamkin of West Orange, NJ is reported in the CMS Open Payments database as having received $13,456 across 382 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,438 97
2024 General $1,216 68
2023 General $1,279 61
2022 General $795 54
2021 General $416 28
2020 General $468 29
2019 General $845 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Irene Mamkin
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Irene Mamkin were reported at $8,438. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Irene Mamkin Pediatric Endocrinology median Middle half National median
2019 $845 $196 $68–$845 $163
2020 $468 $124 $37–$722 $114
2021 $416 $134 $35–$691 $132
2022 $795 $177 $47–$726 $149
2023 $1,279 $236 $75–$887 $160
2024 $1,216 $259 $91–$979 $164
2025 $8,438 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $3,865 19 payments
  2. Sanofi-Aventis U.S. LLC $3,255 23 payments
  3. Novo Nordisk Inc $859 44 payments
  4. AbbVie, Inc. $763 56 payments
  5. Pfizer Inc. $572 22 payments
  6. Insulet Corporation $472 12 payments
  7. Alexion Pharmaceuticals, Inc. $382 15 payments
  8. Dexcom, Inc. $302 12 payments
  9. BioMarin Pharmaceutical Inc. $271 12 payments
  10. Lilly USA, LLC $259 19 payments
  11. Other $2,456 148 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,133 371 payments
  2. Consulting Fee $5,225 2 payments
  3. Travel and Lodging $1,086 8 payments
  4. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. CRENESSITY $3,850 18 payments
  2. LUPRON DEPOT $662 49 payments
  3. NGENLA $480 17 payments
  4. Sogroya $347 15 payments
  5. TZIELD $337 20 payments
  6. BAQSIMI $259 19 payments
  7. Norditropin $258 18 payments
  8. Omnipod $253 6 payments
  9. SKYTROFA $241 15 payments
  10. GENOTROPIN $233 13 payments
  11. Other $3,312 185 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

382 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record